Skyhawk Therapeutics Announces its Founding Scientific Advisory Board Chairman Receives the American Cancer Society's 2026 Medal of Honor

Dr. Tyler Jacks, founding chairman of Skyhawk's Scientific Advisory Board, receives the American Cancer Society's highest award, the Medal of Honor, first awarded in 1949, for his tireless commitment to addressing the complexities of cancer.

BOSTON, March 30, 2026 /PRNewswire/ -- Skyhawk Therapeutics, Inc., a clinical-stage biotechnology company developing novel small molecule therapies to modulate critical RNA targets for a series of challenging diseases, announces that the American Cancer Society (ACS) has awarded the 2026 Medal of Honor to Dr. Tyler Jacks, founding Chairman of Skyhawk's Scientific Advisory Board, founder of the David H. Koch Institute for Integrative Cancer Research at the Massachusetts Institute of Technology (MIT) and professor of biology at MIT. The Medal of Honor is the most prestigious award given by ACS to distinguished individuals who have made valuable contributions in basic, clinical, translational, or population science and whose work has led to advancement in cancer prevention, diagnosis, treatment, or survivorship to improve the lives of patients.